Global biopharmaceutical leader Bristol Myers Squibb (BMS) has announced an expanded collaboration with technology giant NVIDIA. The Bristol Myers Squibb and NVIDIA partnership aims to build the life sciences industry’s most advanced AI factory using NVIDIA DGX Vera Rubin NVL72 systems. It aims to accelerate drug discovery, improve research efficiency, and help Bristol Myers Squibb develop next-generation medicines faster across oncology, neuroscience, immunology, and other disease areas.
BMS is the first life sciences company to acquire a Vera Rubin-based DGX SuperPOD. This advanced pharmaceutical AI infrastructure is set to become the most powerful and energy-efficient single-owned NVIDIA AI system in the life sciences sector, accelerating pharmaceutical R&D innovation across the globe.
Inside the New Bristol Myers Squibb AI Factory
The newly created Bristol Myers Squibb AI factory combines BMS’s existing supercomputing setup with NVIDIA’s latest hardware architecture. By integrating eight DGX Vera Rubin NVL72 rack-scale systems, which house 576 GPUs, the unified platform delivers up to 10 times greater performance per megawatt compared to previous infrastructure.
This deployment in pharmaceutical AI gives scientists across all BMS global sites unified access to high-performance NVIDIA healthcare AI tools. Researchers can utilize the NVIDIA BioNeMo platform for biological modeling, run massive predictions, and streamline complex workloads through plain-English commands.
Bristol Myers Squibb and Nvidia Partnership Expands AI Drug Discovery
The BMS NVIDIA collaboration directly addresses critical issues in early-stage research. By implementing an AI-driven “Predict First” strategy, scientists can run computational models to evaluate molecules before launching physical laboratory experiments.
Key advantages of applying AI in drug discovery include:
- Automated Target Identification: AI agents process massive datasets, saving researchers weeks of manual effort.
- Expanded Compound Libraries: Machine learning has accelerated the development of BMS’s CELMoD compounds, which selectively degrade disease-causing proteins.
- Optimized Molecule Selection: Predictive tools filter out weak candidates early, ensuring lab testing focuses on molecules with the highest probability of success.
“Drug discovery is a sequence of decisions made under uncertainty, and better decisions come from better evidence, faster,” said Robert Plenge, Executive Vice President and Chief Research Officer at BMS. “This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis.”
AI Co-Scientists and Humans Work Together In BMS AI Factory
The Bristol Myers Squibb and Nvidia partnership advances a model of “hybrid intelligence,” where digital systems and human experts work together. While AI co-scientists manage data-intensive simulations and agentic workflows, human researchers focus their attention on high-level strategic decisions.
“We’re committed to translating AI into real outcomes for patients, which requires infrastructure built to match that ambition,” commented Greg Meyers, Chief Digital and Technology Officer at BMS.
Competition in Global Pharma AI Investments Market
Pharmaceutical giants are rapidly scaling supercomputing capabilities to gain a competitive edge. While Eli Lilly established a $1 billion AI co-innovation lab with NVIDIA and Roche launched a hybrid-cloud AI factory, BMS has secured a distinct milestone.
Similar strategic alliances across the industry highlight how leading drugmakers are combining computational power with novel therapeutic platforms.
BMS AI Factory Accelerates Benefits for Patients
Ultimately, the Bristol Myers Squibb and Nvidia partnership aims to deliver faster, more effective treatments to patients. Early estimates suggest AI tools can reduce the timeline required to generate clinical-stage molecules by 20% to 30%.
These advancements will directly impact major therapeutic areas:
- Oncology & Hematology: Designing targeted treatments for hard-to-treat cancers.
- Neuroscience: Accelerating drug discovery for complex conditions like Alzheimer’s disease.
- Immunology & Cardiovascular Disease: Refining biological targets to lower clinical trial failure rates.
What Lies Ahead?
Although financial details of the Bristol Myers Squibb and Nvidia partnership remain undisclosed, BMS plans to scale its proprietary AI models using decades of internal clinical data.
By pairing massive computational scale with human judgment, the BMS Nvidia collaboration sets a clear benchmark for the future of modern medicine.
